We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Self-Teaching AI Algorithm Uses Pathology Images to Diagnose Rare Diseases

By LabMedica International staff writers
Posted on 11 Oct 2022
Print article
Image: New model acts as search engine for large databases of pathology images (Photo courtesy of Brigham and Women’s Hospital)
Image: New model acts as search engine for large databases of pathology images (Photo courtesy of Brigham and Women’s Hospital)

Rare diseases are often difficult to diagnose and predicting the best course of treatment can be challenging for clinicians. Modern electronic databases can store an immense amount of digital records and reference images, particularly in pathology through whole slide images (WSIs). However, the gigapixel size of each individual WSI and the ever-increasing number of images in large repositories, means that search and retrieval of WSIs can be slow and complicated. As a result, scalability remains a pertinent roadblock for efficient use. To solve this issue, researchers have now developed a deep learning algorithm that can teach itself to learn features which can then be used to find similar cases in large pathology image repositories.

Known as SISH (Self-Supervised Image search for Histology), the new tool developed by investigators at Brigham and Women’s Hospital (Boston, MA, USA) acts like a search engine for pathology images and has many potential applications, including identifying rare diseases and helping clinicians determine which patients are likely to respond to similar therapies. The algorithm teaches itself to learn feature representations which can be used to find cases with analogous features in pathology at a constant speed regardless of the size of the database.

In their study, the researchers tested the speed and ability of SISH to retrieve interpretable disease subtype information for common and rare cancers. The algorithm successfully retrieved images with speed and accuracy from a database of tens of thousands of whole slide images from over 22,000 patient cases, with over 50 different disease types and over a dozen anatomical sites. The speed of retrieval outperformed other methods in many scenarios, including disease subtype retrieval, particularly as the image database size scaled into the thousands of images. Even while the repositories expanded in size, SISH was still able to maintain a constant search speed.

The self-teaching algorithm, however, has some limitations including a large memory requirement, limited context awareness within large tissue slides and the fact that it is limited to a single imaging modality. Overall, the algorithm demonstrated the ability to efficiently retrieve images independent of repository size and in diverse datasets. It also demonstrated proficiency in diagnosis of rare disease types and the ability to serve as a search engine to recognize certain regions of images that may be relevant for diagnosis. This work may greatly inform future disease diagnosis, prognosis, and analysis.

“We show that our system can assist with the diagnosis of rare diseases and find cases with similar morphologic patterns without the need for manual annotations, and large datasets for supervised training,” said senior author Faisal Mahmood, PhD, in the Brigham’s Department of Pathology. “This system has the potential to improve pathology training, disease subtyping, tumor identification, and rare morphology identification.”

“As the sizes of image databases continue to grow, we hope that SISH will be useful in making identification of diseases easier,” added Mahmood. “We believe one important future direction in this area is multimodal case retrieval which involves jointly using pathology, radiology, genomic and electronic medical record data to find similar patient cases.”

Related Links:
Brigham and Women’s Hospital 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.